LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire.com/ — The global Pergoveris market has shown impressive growth and is poised to continue expanding in the coming years, driven primarily by the rising prevalence of infertility and increasing demand for assisted reproductive technologies (ART). According to The Business Research Company’s latest Pergoveris Global Market Report 2025, the market’s trajectory is set to climb further, underpinned by several key trends and factors.
Historic Market Growth and Projections
The Pergoveris market is projected to grow substantially, expanding from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Key contributors to this growth include:
- Rising infertility rates globally
- Advancements in ART techniques and technologies
- Increased awareness and acceptance of fertility treatments
- Higher healthcare spending across both developed and emerging markets
- Lifestyle factors, including delayed pregnancies due to career and personal choices
Looking ahead, the market is expected to maintain a strong growth pace with a future CAGR of XX% from 2025 to 2029, reaching $XX million by 2029. The primary drivers for this future growth include:
- Technological innovations in fertility drugs
- Growing adoption of in-vitro fertilization (IVF) techniques
- Expansion of healthcare coverage in emerging economies
- Increased prevalence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis
- Increased research investment in reproductive health
The Role of Infertility in Market Growth
Infertility remains a critical driver of the Pergoveris market. As infertility challenges become more widespread, the demand for effective treatments such as Pergoveris has surged. Contributing factors to the global rise in infertility include:
Delayed childbearing due to changing societal norms and career-focused lifestyles
Exposure to environmental toxins impacting fertility
A growing number of medical conditions that affect fertility, such as PCOS and endometriosis
Pergoveris, a key treatment option for women with severe gonadotropin deficiency, works by enhancing ovarian function through a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), aiding in egg development. The World Health Organization reports that approximately 17.5% of the global adult population—equating to 1 in 6 individuals—experiences infertility, highlighting the growing need for fertility treatments like Pergoveris.
Related topics:
FEMM Offers Ethical and Holistic Alternatives to IVF for Infertility
